Identification of immune‐enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma-Reference-Cited by-同舟云学术

Identification of immune‐enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma

Published:2020-01-29 Issue:5 Volume:24 Page:2819-2831
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Zheng Mingjun¹²³,Hu Yuexin¹²,Gou Rui¹²^ORCID,Liu Ouxuan¹²,Nie Xin¹²,Li Xiao¹²,Liu Qing¹²,Hao Yingying¹²,Liu Juanjuan¹²,Lin Bei¹²^ORCID

Affiliation:

1. Department of Gynaecology and Obstetrics Shengjing Hospital Affiliated to China Medical University Shenyang China

2. Key Laboratory Of Maternal‐Fetal Medicine of Liaoning Province Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province Shenyang China

3. Department of Obstetrics and Gynecology University Hospital LMU Munich Munich Germany

Funder

Shengjing Freedom researchers’ plan

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.14830

Reference38 articles.

1. The epidemiology of ovarian cancer;Banks E;Methods Mol Med,2001

2. Ovarian cancer

3. NCI.SEER Cancer Statistics Review 1975‐2014.2017.

4. Microenvironmental regulation of tumor progression and metastasis

5. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative molecular subtypes of multiple signaling pathways in colon cancer and validation of FMOD as a prognostic-related marker;Journal of Cancer Research and Clinical Oncology;2023-07-20

2. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs;Computers in Biology and Medicine;2023-06

3. COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy;Thoracic Cancer;2023-04-02

4. Early Stage Finding of an Immune-Enhanced Genetic Subtype of Nonsmall Cell Lung Cancer Related with T-Cell Depletion;Evidence-Based Complementary and Alternative Medicine;2022-10-14

5. Definition of immune molecular subtypes with distinct immune microenvironment, recurrence, and PANoptosis features to aid clinical therapeutic decision-making;Frontiers in Genetics;2022-10-13